Search research articles
Contact Us
Filters
Showing results (211-220 of 304) with videos related to
Page
of 31
Sort By:
International Journal of Cancer
|
September 29, 2000
BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas
S van der Flier, C M Chan, A Brinkman, et al.
Endocrine-Related Cancer
|
December 3, 2005
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
L-A Martin, S Pancholi, C M W Chan, et al.
Lancet (London, England)
|
December 18, 1993
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
S R Johnston, B P Haynes, I E Smith, et al.
Cancer Research
|
April 1, 1987
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route
M Dowsett, P E Goss, T J Powles, et al.
Psycho-Oncology
|
April 18, 2000
Communication styles in the cancer consultation: preferences for a patient-centred approach
S M Dowsett, J L Saul, P N Butow, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology
|
January 1, 1992
Comparison of four immunochemical methods for the measurement of oestrogen receptor levels in breast cancer
C M Ryde, D Smith, N King, et al.
Oncogene
|
June 10, 2010
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
I Plaza-Menacho, A Morandi, D Robertson, et al.
Breast Cancer Research and Treatment
|
January 1, 1992
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
P E Lønning, M Dowsett, A Jones, et al.
British Journal of Cancer
|
October 1, 1985
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients
M Dowsett, A L Harris, R Stuart-Harris, et al.
International Journal of Cancer
|
April 3, 1999
Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts
S Detre, J Salter, D M Barnes, et al.
Page
of 31
Search research articles
Search
Showing results (211-220 of 304) with videos related to
Sort By:
Page
of 31
International Journal of Cancer
|
September 29, 2000
BCAR1/p130Cas expression in untreated and acquired tamoxifen-resistant human breast carcinomas
S van der Flier, C M Chan, A Brinkman, et al.
Endocrine-Related Cancer
|
December 3, 2005
The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
L-A Martin, S Pancholi, C M W Chan, et al.
Lancet (London, England)
|
December 18, 1993
Acquired tamoxifen resistance in human breast cancer and reduced intra-tumoral drug concentration
S R Johnston, B P Haynes, I E Smith, et al.
Cancer Research
|
April 1, 1987
Use of the aromatase inhibitor 4-hydroxyandrostenedione in postmenopausal breast cancer: optimization of therapeutic dose and route
M Dowsett, P E Goss, T J Powles, et al.
Psycho-Oncology
|
April 18, 2000
Communication styles in the cancer consultation: preferences for a patient-centred approach
S M Dowsett, J L Saul, P N Butow, et al.
Cytopathology : Official Journal of the British Society for Clinical Cytology
|
January 1, 1992
Comparison of four immunochemical methods for the measurement of oestrogen receptor levels in breast cancer
C M Ryde, D Smith, N King, et al.
Oncogene
|
June 10, 2010
Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance
I Plaza-Menacho, A Morandi, D Robertson, et al.
Breast Cancer Research and Treatment
|
January 1, 1992
Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment
P E Lønning, M Dowsett, A Jones, et al.
British Journal of Cancer
|
October 1, 1985
A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients
M Dowsett, A L Harris, R Stuart-Harris, et al.
International Journal of Cancer
|
April 3, 1999
Time-related effects of estrogen withdrawal on proliferation- and cell death-related events in MCF-7 xenografts
S Detre, J Salter, D M Barnes, et al.
Page
of 31